this post was submitted on 10 Dec 2025
1 points (100.0% liked)

China News

71 readers
12 users here now

A community for china news

founded 1 month ago
MODERATORS
 

US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma’s unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including...


From China - South China Morning Post via This RSS Feed.

no comments (yet)
sorted by: hot top controversial new old
there doesn't seem to be anything here